Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

44.90
+2.295.37%
Volume:2.55M
Turnover:115.27M
Market Cap:2.87B
PE:-11.23
High:46.18
Open:43.53
Low:43.35
Close:42.61
52wk High:49.77
52wk Low:18.53
Shares:63.93M
Float Shares:42.92M
Volume Ratio:1.11
T/O Rate:5.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9990
EPS(LYR):-2.7500
ROE:-73.25%
ROA:-38.12%
PB:7.20
PE(LYR):-16.33

Loading ...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06

Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares

Reuters
·
Dec 05

Vera Therapeutics Inc : JP Morgan Raises Target Price to $99 From $52

THOMSON REUTERS
·
Dec 03

Will Vera Therapeutics (VERA) Strengthen Its Commercial Edge With Board Appointment of James R. Meyers?

Simply Wall St.
·
Dec 01

A Fresh Look at Vera Therapeutics (VERA) Valuation as Analyst Optimism Follows Board Addition and FDA Milestone

Simply Wall St.
·
Nov 29

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Reuters
·
Nov 27

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to Its Board of Directors

THOMSON REUTERS
·
Nov 27

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation

TIPRANKS
·
Nov 26

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Nov 26

Buy Recommendation for Vera Therapeutics: Atacicept’s Market Potential and Efficacy Drive Positive Outlook

TIPRANKS
·
Nov 26

Vera Therapeutics Executive Makes a Noteworthy Stock Sale

TIPRANKS
·
Nov 26

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Nov 24

Vera Therapeutics Q3 EPS USD -1.26 Vs. IBES Estimate USD -1.17

Reuters
·
Nov 20

Vera Therapeutics (VERA): Valuation Insights Following Positive Phase 3 Data, FDA Filing, and Yale Investment

Simply Wall St.
·
Nov 16

Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data

Simply Wall St.
·
Nov 15

Vera Therapeutics SVP Finance Joseph R. Young Reports Sale of Common Shares

Reuters
·
Nov 14

Stock Track | Vera Therapeutics Soars 7.48% on FDA Application for Kidney Disease Treatment Atacicept

Stock Track
·
Nov 10

Stock Track | Vera Therapeutics Soars 5.83% Pre-market on FDA Application for Kidney Disease Treatment

Stock Track
·
Nov 10

Vera Therapeutics to Present at TD Cowen Immunology & Inflammation Summit

Reuters
·
Nov 10

Vera Therapeutics Submits Kidney Disease Therapy Biologics License Application to FDA; Shares Up Pre-Bell

MT Newswires Live
·
Nov 10